Analysts Set Expectations for Xencor, Inc.’s Q2 2022 Earnings (NASDAQ:XNCR)

Xencor, Inc. (NASDAQ:XNCR) – Research analysts at Wedbush issued their Q2 2022 EPS estimates for shares of Xencor in a research note issued on Tuesday, January 11th. Wedbush analyst D. Nierengarten expects that the biopharmaceutical company will post earnings per share of ($0.83) for the quarter. Wedbush also issued estimates for Xencor’s Q3 2022 earnings at ($0.81) EPS and Q4 2022 earnings at ($0.79) EPS.

A number of other research analysts have also recently commented on the stock. TheStreet cut shares of Xencor from a “c” rating to a “d+” rating in a report on Friday, November 26th. HC Wainwright began coverage on shares of Xencor in a research report on Wednesday, December 15th. They set a “buy” rating and a $61.00 price objective for the company. Piper Sandler cut their target price on Xencor from $75.00 to $71.00 and set an “overweight” rating on the stock in a report on Tuesday, November 9th. Zacks Investment Research cut Xencor from a “buy” rating to a “hold” rating in a research note on Friday, November 12th. Finally, BTIG Research reiterated a “buy” rating on shares of Xencor in a research note on Tuesday, November 9th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, Xencor presently has a consensus rating of “Buy” and an average price target of $52.67.

Shares of XNCR opened at $37.05 on Thursday. Xencor has a 1-year low of $30.12 and a 1-year high of $58.35. The company has a market cap of $2.17 billion, a price-to-earnings ratio of -370.50 and a beta of 0.76. The company’s fifty day simple moving average is $37.72 and its 200 day simple moving average is $35.62.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings results on Monday, November 8th. The biopharmaceutical company reported ($0.69) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.06. Xencor had a negative net margin of 2.53% and a negative return on equity of 0.68%. The company had revenue of $19.68 million during the quarter, compared to analysts’ expectations of $17.63 million. During the same quarter in the previous year, the company earned ($0.22) EPS.

A number of large investors have recently made changes to their positions in the stock. Baillie Gifford & Co. raised its position in shares of Xencor by 39.3% during the 3rd quarter. Baillie Gifford & Co. now owns 1,259 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 355 shares during the last quarter. Lazard Asset Management LLC boosted its position in Xencor by 43.0% during the 2nd quarter. Lazard Asset Management LLC now owns 1,833 shares of the biopharmaceutical company’s stock worth $62,000 after purchasing an additional 551 shares during the period. KBC Group NV purchased a new stake in Xencor during the 3rd quarter worth $97,000. PNC Financial Services Group Inc. lifted its holdings in Xencor by 54.4% in the 3rd quarter. PNC Financial Services Group Inc. now owns 3,953 shares of the biopharmaceutical company’s stock worth $129,000 after buying an additional 1,393 shares in the last quarter. Finally, Amundi acquired a new position in Xencor in the 2nd quarter worth $138,000. Hedge funds and other institutional investors own 98.16% of the company’s stock.

In other Xencor news, CMO Allen Yang sold 3,664 shares of the company’s stock in a transaction on Friday, December 17th. The stock was sold at an average price of $36.62, for a total transaction of $134,175.68. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 3.68% of the stock is owned by corporate insiders.

Xencor Company Profile

Xencor, Inc engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions.

Featured Story: How is inflation measured?

Earnings History and Estimates for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.